Biomedical Research Education & Training
Faculty Member

Giltnane, Jennifer, MD, PhD
Instructor in Pathology, Microbiology and Immunology

Lab Url: N/A

Phone Number: 615-875-1004

Email Address: jennifer.giltnane@vanderbilt.edu

Giltnane, Jennifer's picture
Academic history
Pre-doctoral CRTA, National Cancer Institute
Residency, Vanderbilt University School of Medicine
BS, summa cum laude, University of Tennessee, Knoxville, TN
Masters Phil., Yale University Graduate School of Arts & Sciences
Postdoctoral Fellowship, Vanderbilt-Ingram Cancer Center
M.D. and Ph.D., Yale University School of Medicine

Office Address   Mailing Address

PRB 649

777 Preston Research Building 37232-6307


Patient Care Specialty
Anantomic Pathology, Laboratory Medicine, Clinical Pathology

Research Specialty
Predictive biomarker discovery and validation for translational oncology research

Research Description
I am continuing my career at Vanderbilt with a focus on biomarker discovery and validation for the prediction of treatment resistance and recurrence in breast cancer. Currently, I am exploring the mechanisms of resistance to endocrine therapy, utilizing the accrued tissue in the BRE0776 presurgical letrozole trial as part of the VICC's Breast SPORE. Through multi-platform molecular profiling of these tumors, I hope to identify actionable somatic alterations and uncover additional therapeutic liabilities to overcome endocrine resistance in early breast cancer. A long-term goal is to develop a cost-effective, protein-based biomarker assay to predict endocrine-response in ER+ breast cancer, informed by my experience with quantitative protein measurements in tissue.

Clinical Interests
Biobanking and tissue management for clinical studies, tissue microarray studies of clinical trial cohorts

Publications
David L. Rimm, Jennifer M. Giltnane, Lisa Ryden. Methods for a Predictive Diagnostic Test for Tamoxifen. U.S. Patent Application #12/215,458. Filed: 1/29/2007. http://www.google.com/patents/US20090155767

Chmielecki, J, Peifer, M, Viale, A, Hutchinson, K, Giltnane, J, Socci, ND, Hollis, CJ, Dean, RS, Yenamandra, A, Jagasia, M, Kim, AS, Dav??, UP, Thomas, RK, Pao, W. Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm. Genes Chromosomes Cancer, 51(1), 54-65, 2012

Anagnostou, VK, Welsh, AW, Giltnane, JM, Siddiqui, S, Liceaga, C, Gustavson, M, Syrigos, KN, Reiter, JL, Rimm, DL. Analytic variability in immunohistochemistry biomarker studies. Cancer Epidemiol Biomarkers Prev, 19(4), 982-91, 2010 PMCID:2894764

Rokicki, J, Das, PM, Giltnane, JM, Wansbury, O, Rimm, DL, Howard, BA, Jones, FE. The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium. Mol Cancer, 9, 150, 2010 PMCID:2894764

Giltnane, JM, Moeder, CB, Camp, RL, Rimm, DL. Quantitative multiplexed analysis of ErbB family coexpression for primary breast cancer prognosis in a large retrospective cohort. Cancer, 115(11), 2400-9, 2009 PMCID:2756449

Moeder, CB, Giltnane, JM, Moulis, SP, Rimm, DL. Quantitative, fluorescence-based in-situ assessment of protein expression. Methods Mol Biol, 520, 163-75, 2009 PMCID:2894764

Giltnane, JM, Molinaro, A, Cheng, H, Robinson, A, Turbin, D, Gelmon, K, Huntsman, D, Rimm, DL. Comparison of quantitative immunofluorescence with conventional methods for HER2/neu testing with respect to response to trastuzumab therapy in metastatic breast cancer. Arch Pathol Lab Med, 132(10), 1635-47, 2008 PMCID:2756449

Nadler, Y, Camp, RL, Giltnane, JM, Moeder, C, Rimm, DL, Kluger, HM, Kluger, Y. Expression patterns and prognostic value of Bag-1 and Bcl-2 in breast cancer. Breast Cancer Res, 10(2), R35, 2008 PMCID:2397537

*Moeder, CB, *Giltnane, JM, Harigopal, M, Molinaro, A, Robinson, A, Gelmon, K, Huntsman, D, Camp, RL, Rimm, DL. *Authors contributed equally . Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol, 25(34), 5418-25, 2007 PMCID:2397537

Giltnane, JM, Ryd??n, L, Cregger, M, Bendahl, PO, Jirstr??m, K, Rimm, DL. Quantitative measurement of epidermal growth factor receptor is a negative predictive factor for tamoxifen response in hormone receptor positive premenopausal breast cancer. J Clin Oncol, 25(21), 3007-14, 2007 PMCID:2397537

Pick, E, Kluger, Y, Giltnane, JM, Moeder, C, Camp, RL, Rimm, DL, Kluger, HM. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Res, 67(7), 2932-7, 2007 PMCID:2397537

Rimm, DL, Giltnane, JM, Moeder, C, Harigopal, M, Chung, GG, Camp, RL, Burtness, B. Bimodal population or pathologist artifact (Letter to the editor). J Clin Oncol, 25(17), 2487-8, 2007 PMCID:2397537

Dolled-Filhart, M, McCabe, A, Giltnane, J, Cregger, M, Camp, RL, Rimm, DL. Quantitative in situ analysis of beta-catenin expression in breast cancer shows decreased expression is associated with poor outcome. Cancer Res, 66(10), 5487-94, 2006 PMCID:2397537

Giltnane, JM, Murren, JR, Rimm, DL, King, BL. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray. Histopathology, 49(2), 161-9, 2006 PMCID:2397537

Cahir-McFarland, ED, Carter, K, Rosenwald, A, Giltnane, JM, Henrickson, SE, Staudt, LM, Kieff, E. Role of NF-kappa B in cell survival and transcription of latent membrane protein 1-expressing or Epstein-Barr virus latency III-infected cells. J Virol, 78(8), 4108-19, 2004 PMCID:374271

Giltnane, JM, Rimm, DL. Technology insight: Identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol, 1(2), 104-11, 2004 PMCID:2397537

Kovanen, PE, Rosenwald, A, Fu, J, Hurt, EM, Lam, LT, Giltnane, JM, Wright, G, Staudt, LM, Leonard, WJ. Analysis of gamma c-family cytokine target genes. Identification of dual-specificity phosphatase 5 (DUSP5) as a regulator of mitogen-activated protein kinase activity in interleukin-2 signaling. J Biol Chem, 278(7), 5205-13, 2003 PMCID:309637

McConnell, MJ, Chevallier, N, Berkofsky-Fessler, W, Giltnane, JM, Malani, RB, Staudt, LM, Licht, JD. Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression. Mol Cell Biol, 23(24), 9375-88, 2003 PMCID:309637

Rosenwald, A, Wright, G, Wiestner, A, Chan, WC, Connors, JM, Campo, E, Gascoyne, RD, Grogan, TM, Muller-Hermelink, HK, Smeland, EB, Chiorazzi, M, Giltnane, JM, Hurt, EM, Zhao, H, Averett, L, Henrickson, S, Yang, L, Powell, J, Wilson, WH, Jaffe, ES, Simon, R, Klausner, RD, Montserrat, E, Bosch, F, Greiner, TC, Weisenburger, DD, Sanger, WG, Dave, BJ, Lynch, JC, Vose, J, Armitage, JO, Fisher, RI, Miller, TP, LeBlanc, M, Ott, G, Kvaloy, S, Holte, H, Delabie, J, Staudt, LM. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell, 3(2), 185-97, 2003 PMCID:309637

Rosenwald, A, Wright, G, Chan, WC, Connors, JM, Campo, E, Fisher, RI, Gascoyne, RD, Muller-Hermelink, HK, Smeland, EB, Giltnane, JM, Hurt, EM, Zhao, H, Averett, L, Yang, L, Wilson, WH, Jaffe, ES, Simon, R, Klausner, RD, Powell, J, Duffey, PL, Longo, DL, Greiner, TC, Weisenburger, DD, Sanger, WG, Dave, BJ, Lynch, JC, Vose, J, Armitage, JO, Montserrat, E, L??pez-Guillermo, A, Grogan, TM, Miller, TP, LeBlanc, M, Ott, G, Kvaloy, S, Delabie, J, Holte, H, Krajci, P, Stokke, T, Staudt, LM, , . The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med, 346(25), 1937-47, 2002 PMCID:309637

Shaffer, AL, Lin, KI, Kuo, TC, Yu, X, Hurt, EM, Rosenwald, A, Giltnane, JM, Yang, L, Zhao, H, Calame, K, Staudt, LM. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity, 17(1), 51-62, 2002 PMCID:309637


Postdoctoral Position Available
Yes

Postdoctoral Position Details
No position available at this time.

Updated Date
04/12/2013